摘要
目的:探讨降钙素原(PCT)对慢性阻塞性肺疾病急性加重期(AECOPD)抗生素使用的指导意义。方法:选取2013年1-12月笔者所在医院收治的AECOPD患者248例,采用随机数字表法将其分为PCT组(132例)和常规组(116例),常规组抗生素的使用由医师根据指南决定,而PCT组则根据患者PCT的水平来决定抗生素的使用。比较两组患者痰培养结果、抗生素的使用情况及临床治疗结果。结果:两组病原菌分布比较差异无统计学意义(P>0.05)。常规组的限制性或特殊使用级别的抗生素较多,常规组使用β内酰胺酶抑制剂或青霉素类(含酶抑制剂)明显高于PCT组,差异有统计学意义(P<0.05);且PCT组患者的住院费用、抗生素费用以及抗生素的使用率均低于常规组,差异有统计学意义(P<0.05)。两组患者的住院时间、住ICU例数、临床好转率、住院病死率比较差异无统计学意义(P>0.05)。结论:PCT能够指导AECOPD抗生素的使用,能够减少抗生素的使用率,降低住院费用以及抗生素费用,不影响患者的预后。
Objective：To investigate procalcitonin （PCT） on acute exacerbation of chronic obstructive pulmonary disease （AECOPD） antibiotic use guidance. Method：From January to December 2013 in author’s hospital in 248 cases of AECOPD,by using the method to random number table divided into PCT group（132 cases） and normal group（116 cases）,the normal group of antibiotics determined by physicians according to the guidelines,while PCT group according to patients with PCT to determine the level of use of antibiotics. Compared two groups of patients with sputum culture results,the usage of antibiotics and clinical treatment.Result：Two groups of pathogens had no significant difference（P〉0.05）. The normal group limited or special use level of more conventional antibiotics, usingβlactamase inhibitors or penicillin（containing enzyme inhibitor） was significantly higher than that in PCT group,the difference was statistically significant （P〈0.05）;and PCT group hospitalization costs,costs of antibiotics and antibiotic use rates were lower than the normal group,the difference was statistically significant（P〈0.05）. Two groups of hospitalization time,live ICU cases,clinical improvement rate,hospital mortality rate had no significant difference（P〉0.05）. Conclusion：PCT can be used to guide AECOPD antibiotics,can reduce the use of antibiotics,reduce hospitalization expenses and costs of antibiotic,does not affect the prognosis of patients.
出处
《中外医学研究》
2014年第20期1-3,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
惠州市科技计划项目(项目编号:20120801)
关键词
降钙素原
慢性阻塞性肺疾病
急性加重期
抗生素
Procalcitonin
Chronic obstructive pulmonary disease
Acute exacerbation
Antibiotics
